Table 1 Neurological characteristics of the patients on study entry (overall and by genotype, AT vs. AA)

Number of patients

19

21

5

14

Age at study entry (years)

60 [54–64]

61 [54–66]

62 [61–62]

61 [53–66]

Gender (F/M)

6/13

9/12

3/2

6/10

Time since diagnosis (years)

2 [1–3]

2 [1–3]

2 [1–3]

2 [1–3]

Hoehn and Yahr stage (range, 1–5)

2 [1.5-2]

2 [1.5-2]

2 [1.5-2]

2 [1.4-2]

Daily L-dopa dose equivalent (mg)

300 [162–510]

300 [150–532]

300 [150–532]

300 [150–532]

Patients on L-dopa (n)

9

10

3

7

Patients on dopaminergic agonists (n, mean daily L-dopa equivalent in mg)

18 (243)

18 (220)

4 (225)

13 (250)

Patients on L-dopa and agonists (n)

7

7

2

5

Patients on rasagiline (n)

3

3

1

2

Mini Mental Scale Examination score

29 [28–30]

28 [26–30]

28 [27–29]

28 [26–30]

Mattis Dementia Rating Scale score

139 [138–141]

139 [134–143]

139 [138–140]

139 [133–143]

Epworth Sleepiness Scale score

9 [7–13]

9 [5–13]

8 [6–10]

9 [5–13]

Montgomery Asberg Depression Rating Scale

3 [2–4]

4 [2–5]

3 [2–5]

4 [2–5]

Cognition and behavior: MDS-UPDRS part I score

6 [5–8]

6 [4.7-9]

5 [4–7]

6 [4.7-9]